Ono Pharmaceutical Co., Ltd. (OPHLY)
USD 4.16
(2.46%)
USD 4.16
(2.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -157.27 Billion JPY | -80.85% |
| 2023 | -86.96 Billion JPY | -44.2% |
| 2022 | -60.31 Billion JPY | -16.0% |
| 2021 | -51.99 Billion JPY | 14.27% |
| 2020 | -60.64 Billion JPY | -4.95% |
| 2019 | -57.78 Billion JPY | 10.5% |
| 2018 | -64.56 Billion JPY | 55.58% |
| 2017 | -145.35 Billion JPY | -32.58% |
| 2016 | -109.64 Billion JPY | -5.81% |
| 2015 | -103.61 Billion JPY | 0.29% |
| 2014 | -103.92 Billion JPY | -332.54% |
| 2013 | -24.02 Billion JPY | -14.7% |
| 2012 | -20.94 Billion JPY | 6.62% |
| 2011 | -22.43 Billion JPY | -45.93% |
| 2010 | -15.37 Billion JPY | -9.13% |
| 2009 | -14.08 Billion JPY | 1.07% |
| 2008 | -14.23 Billion JPY | 4.58% |
| 2007 | -14.92 Billion JPY | -0.26% |
| 2006 | -14.88 Billion JPY | 2.13% |
| 2005 | -15.2 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -93.66 Billion JPY | 5.13% |
| 2024 Q2 | -98.73 Billion JPY | -93.41% |
| 2024 Q1 | -51.04 Billion JPY | 41.3% |
| 2024 FY | -157.27 Billion JPY | -80.85% |
| 2024 Q4 | -157.27 Billion JPY | -67.92% |
| 2023 FY | -86.96 Billion JPY | -44.2% |
| 2023 Q4 | -86.96 Billion JPY | 12.77% |
| 2023 Q3 | -99.69 Billion JPY | -11.43% |
| 2023 Q2 | -89.46 Billion JPY | -12.83% |
| 2023 Q1 | -79.29 Billion JPY | -31.47% |
| 2022 Q1 | -40.61 Billion JPY | 21.89% |
| 2022 FY | -60.31 Billion JPY | -16.0% |
| 2022 Q4 | -60.31 Billion JPY | -12.98% |
| 2022 Q3 | -53.37 Billion JPY | 26.03% |
| 2022 Q2 | -72.15 Billion JPY | -77.68% |
| 2021 Q2 | -74.49 Billion JPY | -30.78% |
| 2021 Q1 | -56.96 Billion JPY | 6.07% |
| 2021 Q3 | -78.42 Billion JPY | -5.28% |
| 2021 FY | -51.99 Billion JPY | 14.27% |
| 2021 Q4 | -51.99 Billion JPY | 33.71% |
| 2020 Q3 | -58.22 Billion JPY | -25.8% |
| 2020 FY | -60.64 Billion JPY | -4.95% |
| 2020 Q1 | -31.24 Billion JPY | 45.92% |
| 2020 Q2 | -46.28 Billion JPY | -48.11% |
| 2020 Q4 | -60.64 Billion JPY | -4.16% |
| 2019 Q2 | -77.67 Billion JPY | -24.16% |
| 2019 Q1 | -62.56 Billion JPY | 3.1% |
| 2019 Q3 | -77.46 Billion JPY | 0.27% |
| 2019 FY | -57.78 Billion JPY | 10.5% |
| 2019 Q4 | -57.78 Billion JPY | 25.41% |
| 2018 Q4 | -64.56 Billion JPY | -65.56% |
| 2018 Q2 | -49.47 Billion JPY | 45.98% |
| 2018 Q1 | -91.58 Billion JPY | 36.99% |
| 2018 FY | -64.56 Billion JPY | 55.58% |
| 2018 Q3 | -38.99 Billion JPY | 21.18% |
| 2017 FY | -145.35 Billion JPY | -32.58% |
| 2017 Q4 | -145.35 Billion JPY | -35.26% |
| 2017 Q3 | -107.46 Billion JPY | -13.64% |
| 2017 Q2 | -94.57 Billion JPY | 4.67% |
| 2017 Q1 | -99.2 Billion JPY | 9.52% |
| 2016 Q4 | -109.64 Billion JPY | -9.4% |
| 2016 Q3 | -100.22 Billion JPY | 7.22% |
| 2016 Q1 | -102.54 Billion JPY | 1.04% |
| 2016 FY | -109.64 Billion JPY | -5.81% |
| 2016 Q2 | -108.01 Billion JPY | -5.34% |
| 2015 Q2 | -92.97 Billion JPY | -3.03% |
| 2015 FY | -103.61 Billion JPY | 0.29% |
| 2015 Q1 | -90.23 Billion JPY | 13.17% |
| 2015 Q4 | -103.61 Billion JPY | -24.97% |
| 2015 Q3 | -82.91 Billion JPY | 10.82% |
| 2014 Q3 | -21.22 Billion JPY | 20.2% |
| 2014 Q2 | -26.59 Billion JPY | -14.44% |
| 2014 FY | -103.92 Billion JPY | -332.54% |
| 2014 Q1 | -23.23 Billion JPY | 3.29% |
| 2014 Q4 | -103.92 Billion JPY | -389.74% |
| 2013 Q4 | -24.02 Billion JPY | -23.32% |
| 2013 Q1 | -18.44 Billion JPY | 11.97% |
| 2013 FY | -24.02 Billion JPY | -14.7% |
| 2013 Q3 | -19.48 Billion JPY | -20.36% |
| 2013 Q2 | -16.18 Billion JPY | 12.22% |
| 2012 Q3 | -19.99 Billion JPY | 3.1% |
| 2012 Q1 | -19.31 Billion JPY | 13.9% |
| 2012 Q4 | -20.94 Billion JPY | -4.76% |
| 2012 FY | -20.94 Billion JPY | 6.62% |
| 2012 Q2 | -20.63 Billion JPY | -6.83% |
| 2011 Q2 | -16.06 Billion JPY | -8.46% |
| 2011 FY | -22.43 Billion JPY | -45.93% |
| 2011 Q3 | -32.99 Billion JPY | -105.3% |
| 2011 Q4 | -22.43 Billion JPY | 32.0% |
| 2011 Q1 | -14.81 Billion JPY | 3.62% |
| 2010 Q2 | -12.56 Billion JPY | 0.0% |
| 2010 FY | -15.37 Billion JPY | -9.13% |
| 2010 Q4 | -15.37 Billion JPY | 0.0% |
| 2010 Q3 | -15.37 Billion JPY | -22.33% |
| 2009 Q4 | -14.08 Billion JPY | 12.22% |
| 2009 FY | -14.08 Billion JPY | 1.07% |
| 2009 Q3 | -16.04 Billion JPY | 0.0% |
| 2008 FY | -14.23 Billion JPY | 4.58% |
| 2007 FY | -14.92 Billion JPY | -0.26% |
| 2006 FY | -14.88 Billion JPY | 2.13% |
| 2005 FY | -15.2 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 791.341% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 624.263% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | -9766.688% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 992146.171% |
| Novartis AG | 12.95 Billion USD | 1314.041% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | -92579.753% |